Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer
Recruiting
Observational Study
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 45 – 80
- Sex
- Any
- Study type
- Observational
- Participants needed
- 38 (estimated)
- Sponsor
- Shanghai Chest Hospital of Shanghai Jiao Tong University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study aims to investigate the clinical value of small extracellular vesicle (sEV) miRNAs as predictive biomarkers for immunochemotherapy efficacy in extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC represents a highly aggressive neuroendocrine malignancy, where the current standard first-line treatment combining immune checkpoint inhibitors with chemotherapy lacks predictive biomarke…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Requirements for patients enrolled in the project:
1. The pathological diagnosis of the patient is ESSCLC;
2. ECOG score 0 or 1；
3. The patient is receiving immunotherapy combined with chemotherapy for the first time and has no history of chemotherapy treatment;
4. Patients wit…
Contacts